Anti-PD-L1 therapy yielded durable responses in early NSCLC trials (KCRI is currently enrolling in a AntiPDL1 NSCLC and BC study)

Anti-PD-L1 therapy yielded durable responses in early NSCLC trials

Continue Reading

Hidden Killer Part 1: Why Doctors are Urging People to be Tested for Hepatitis C

Continue Reading

How do you know you have Hepatitis C (or not)?

Continue Reading

Treatment for liver-damaging virus is changing fast. Experts release new guidelines

Continue Reading

Flush those colonoscopy fears

KCRI has several Ulcerative Colitius and Crohn's Disease research study opportunities available. 
 
 
 
Continue Reading

Kansas City Research Institute Introduces Non-Invasive Technology for Liver Disease Diagnosis

Kansas City Research Institute Introduces Non-Invasive Technology
for Liver Disease Diagnosis

 

Non-invasive examination replaces costly, painful biopsy procedure

 

Continue Reading

KCRI Participated in all 3 of these successful trials.

http://goo.gl/MKUJzC

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

 

Continue Reading

Dr. Freilich Behind New Breakthrough Hepatitis C Drug -NPR strory

Continue Reading

Dr. Freilich in the News

http://fox4kc.com/2013/12/12/new-weapon-to-cure-hepatitis-c/

 

KANSAS CITY, Mo. — Hepatitis C is a liver-destroying virus that’s most common in baby boomers. Many got it years ago from IV drug use or unsafe sex. Now there’s a new drug to cure it.

Continue Reading

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab

 

Continue Reading

Pages

Subscribe to RSS - blogs